Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widesp...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Folegatti, P, Bellamy, D, Roberts, R, Powlson, J, Edwards, N, Mair, C, Bowyer, G, Poulton, I, Mitton, C, Green, N, Berrie, E, Lawrie, A, Hill, A, Ewer, K, Hermon-Taylor, J, Gilbert, S
Formaat:	Journal article
Gepubliceerd in:	MDPI 2019

Gelijkaardige items

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
door: Pedro M. Folegatti, et al.
Gepubliceerd in: (2019-05-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
door: Zhang, C, et al.
Gepubliceerd in: (2023)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
door: Sharpe, HR, et al.
Gepubliceerd in: (2022)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
door: Cheng Zhang, et al.
Gepubliceerd in: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
door: Adam Berg, et al.
Gepubliceerd in: (2021-10-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
door: Hannah R. Sharpe, et al.
Gepubliceerd in: (2022-03-01)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens
door: Antrobus, R, et al.
Gepubliceerd in: (2014)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
door: Antrobus, R, et al.
Gepubliceerd in: (2014)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
door: Jinnam Kim, et al.
Gepubliceerd in: (2023-04-01)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
door: Moreira Folegatti, P
Gepubliceerd in: (2021)

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
door: Folegatti, P, et al.
Gepubliceerd in: (2021)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
door: O'Hara, G, et al.
Gepubliceerd in: (2012)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
door: Ashley C. Beavis, et al.
Gepubliceerd in: (2023-07-01)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
door: Folegatti, P, et al.
Gepubliceerd in: (2021)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
door: Bosaeed, M, et al.
Gepubliceerd in: (2021)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
door: Charlotte Davis, et al.
Gepubliceerd in: (2024-06-01)

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
door: Pedro M. Folegatti, et al.
Gepubliceerd in: (2021-07-01)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
door: Dicks, M, et al.
Gepubliceerd in: (2015)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
door: Edmund G.-T. Wee, et al.
Gepubliceerd in: (2024-08-01)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
door: Pedro M. Folegatti, et al.
Gepubliceerd in: (2021-03-01)

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels
door: Alharbi, N, et al.
Gepubliceerd in: (2019)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
door: Jer-Hwa Chang, et al.
Gepubliceerd in: (2022-02-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
door: Hermosilla, E, et al.
Gepubliceerd in: (2022)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
door: Folegatti, PM, et al.
Gepubliceerd in: (2019)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
door: Ting-Yun Lin, et al.
Gepubliceerd in: (2022-08-01)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
door: Tamsin Cargill, et al.
Gepubliceerd in: (2023-11-01)

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
door: Nawamin Pinpathomrat, et al.
Gepubliceerd in: (2022-05-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
door: Ogbe, A, et al.
Gepubliceerd in: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
door: Eduardo Hermosilla, et al.
Gepubliceerd in: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
door: López-Camacho, C, et al.
Gepubliceerd in: (2020)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
door: César López-Camacho, et al.
Gepubliceerd in: (2020-06-01)

Is the ChAdOx1 Vaccine Safe and Immunogenic as Prophylactic Measure Against the Lethal Human-Coronaviruses? A Systematic Review
door: Andréia Michelle Alves Cunha de Alcântar, et al.
Gepubliceerd in: (2023-07-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
door: Ane Ogbe, et al.
Gepubliceerd in: (2022-04-01)

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
door: Alex Olvera, et al.
Gepubliceerd in: (2024-03-01)

Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
door: Nawamin Pinpathomrat, et al.
Gepubliceerd in: (2022-09-01)

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand
door: Kriangkrai Chawansuntati, et al.
Gepubliceerd in: (2024-06-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
door: Folegatti, P, et al.
Gepubliceerd in: (2019)

Simian adenoviruses as vaccine vectors
door: Morris, S, et al.
Gepubliceerd in: (2016)

Simian adenoviruses as vaccine vectors
door: Morris, S, et al.
Gepubliceerd in: (2016)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
door: Folegatti, PM, et al.
Gepubliceerd in: (2020)